Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Neoplasms × pasireotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 3 Neuroendocrine Tumors 3 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Carcinoid Tumor 2 Uveal Melanoma 1 Thyroid Neoplasms 1 Sarcoma, Synovial 1 Prolactinoma 1 Prolactin-Producing Pituitary Tumor 1 Primary Inoperable Thymoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Peritoneal Neoplasms 1 Pancreatic Fistula 1 Neoplasms 1 Nelson Syndrome 1 Myelodysplastic Syndromes 1 Meningioma 1 Lymphoma 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Insulinoma 1 Hypoglycemia 1 Hyperinsulinism 1 Hematologic Neoplasms 1 Gastro-enteropancreatic neuroendocrine tumor 1 Desmoplastic Small Round Cell Tumor 1 Congenital Hyperinsulinism 1

Interventions

Cyclophosphamide 322 Trastuzumab 306 Paclitaxel 272 Docetaxel 242 Capecitabine 208 Letrozole 196 Doxorubicin 165 Carboplatin 162 Tamoxifen 142 Radiotherapy 142 Fulvestrant 132 Epirubicin 125 Anastrozole 121 Surveys and Questionnaires 118 Exercise 111 Vinorelbine 104 palbociclib 96 exemestane 94 Blood Specimen Collection 94 Bevacizumab 93 Magnetic Resonance Spectroscopy 92 pertuzumab 88 pembrolizumab 88 Albumin-Bound Paclitaxel 79 Gemcitabine 76 Drug Therapy 70 Lapatinib 69 Cisplatin 63 Biopsy 63 130-nm albumin-bound paclitaxel 63

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356862 2017-01-25

SOM 230

Alliance Pour La Recherche en Cancerologie

Phase 2 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡